Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes
Renée Maria Saliby(Yale University), David A. Braun(Yale Cancer Center), M. Harry Kane(Broad Institute), Deepak Poduval(Yale University), Brian I. Rini(Vanderbilt University Medical Center), Talal El Zarif(Yale University), Eliezer M. Van Allen(Dana-Farber Cancer Institute), Sumanta K. Pal(City of Hope), Sabina Signoretti(Brigham and Women's Hospital), Soki Kashima(Akita University), Toni K. Choueiri(Harvard University), Valisha Shah(Dana-Farber Cancer Institute), Rana R. McKay(University of California San Diego), Robert J. Motzer(Memorial Sloan Kettering Cancer Center), Maxine Sun(Université de Montréal), Bradley A. McGregor(Harvard University), Wanling Xie(Dana-Farber Cancer Institute), Laurence Albigès(Université Paris-Saclay), Tejas Jammihal(Children's Hospital of Philadelphia), Katherine Sadak(Yale University), Sachet A. Shukla(The University of Texas MD Anderson Cancer Center), Chris Labaki(Beth Israel Deaconess Medical Center), Thomas Powles(National Health Service), Eddy Saad(Dana-Farber Cancer Institute)
Cited by 46
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
|New England Journal of Medicine|2018|4.6k